Biotechnology

Black Bird Biotech Posts Full MiteXstreamTM Biopesticide Efficacy Report

March 3, 2022 8:45 AM

The Company Prepares to Launch a Major Sales Initiative FLOWER MOUND, TX / ACCESSWIRE / March 3, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that it had posted the MiteXstreamTM Efficacy Report published by British Columbia laboratory Botanical Research in Motion (BRIM) at MiteXstream.com. "The power of MiteXstreamTM has now been validated and sets the stage for our...

Read more

Ohio State Installs, Commissions New Pilot-Scale Ultra Shear Technology Processing Equipment for Preparation of Higher Quality and Safer Liquid Foods and Beverages

March 3, 2022 8:15 AM

COLUMBUS, OH / ACCESSWIRE / March 3, 2022 / Food processing companies looking for innovative new ways to preserve clean-label liquid food without artificial preservatives will soon have a new option to do so thanks to new technology being developed at The Ohio State University College of Food, Agricultural, and Environmental Sciences (CFAES) in partnership with scientists and engineers at Pressure BioSciences, Inc. (OTCQB:PBIO), a...

Read more

Apollo Endosurgery to Participate in the Cowen Healthcare Conference

March 2, 2022 7:30 AM

AUSTIN, TX / ACCESSWIRE / March 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that Chas McKhann, CEO, and Jeff Black, CFO, will host investor meetings March 7-8, 2022 as part of the Cowen Healthcare Conference, taking place virtually. As part of the conference event, management will participate in a fireside chat...

Read more

Oncology Pharma Reports on Progress with Ribera Solutions

March 2, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions' Connect2Med. Ribera has segregated the business entity into a separate business unit and made it an independent entity as a Delaware Corporation under the name of Connect2Trials, Inc. Oncology Pharma's investment has been transferred to the new...

Read more

Applied UV Expands Reach into Global Cannabis Market

March 1, 2022 8:00 AM

Recently Acquired Kes Science Continues Cannabis Market Penetration MOUNT VERNON, NY / ACCESSWIRE / March 1, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that its...

Read more

Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

March 1, 2022 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year Dosed first patient in phase 2 gastric study of cinrebafusp alfa; HER2-low arm data expected this year and HER2-high arm data expected in 2023 Dosed first patient in phase 1/2 solid tumor study of PRS-344/S095012 PRS-220 phase 1 initiation on track for this year...

Read more

Medspresso Joins the Speciality Coffee Association of South Africa

February 28, 2022 8:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 28, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: Medspresso™ is pleased to announce its membership in the Speciality Coffee Association of South Africa (SCASA). SCASA is a non-profit organization that brings together coffee...

Read more

Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum

February 25, 2022 8:05 AM

- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery - No venous ulcer recurrences, relapses of CVI, or safety issues - Improvements in average Reflux, disease manifestations (VCSS), and pain (VAS) endpoints continue to be encouraging IRVINE, CA / ACCESSWIRE / February 25, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

Read more

Black Bird Biotech Announces MiteXstreamTM Biopesticide Efficacy Report Findings

February 24, 2022 8:50 AM

BHighly Effective Against Spider Mites, Molds and Mildews; Plant-Based Formula of Strictly Food-Grade Ingredients Shows its Power, Including Capacity to Act as a Repellant FLOWER MOUND, TX / ACCESSWIRE / February 24, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that British Columbia laboratory Botanical Research in Motion (BRIM) had delivered its Efficacy Testing Report on...

Read more

Applied UV Announces Annual Shareholder Meeting Date

February 24, 2022 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / February 24, 2022 / Applied UV, Inc.(NASDAQCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that it will hold its Annual Stockholders Meeting at 100pm EDT on May 17th,...

Read more

MitoChem Therapeutics to Present at Mitochondria-Targeted Drug Development Summit

February 23, 2022 5:45 PM

CHARLESTON, SC / ACCESSWIRE / February 23, 2022 / MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today that Bärbel Rohrer Ph.D., CSO, will present at the Mitochondrial-Targeted Drug Development Summit on Thursday, February 24, 2022 at 11:30am ET. Dr. Rohrer's presentation is titled "Mitochondrial Protective Therapeutics for Neurodegenerative Diseases" and...

Read more

Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

February 23, 2022 8:00 AM

Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal VERO BEACH, FL / ACCESSWIRE / February 23, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has received a payment totaling USD $750,000 from...

Read more

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

February 23, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update. To access...

Read more

Oncology Pharma Releases Further Feasibility Studies, Data and Capacities

February 23, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Development Agreement with NanoSmart Pharmaceuticals, demonstrating the feasibility and the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations. The active...

Read more

BioInvent International AB (publ) Year-End Report January 1 - December 31, 2021

February 23, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / February 23, 2022 / BioInvent International (STO:BINV) "The past year was very exciting for BioInvent. Two of our clinical trials provided highly encouraging results in 2021 at the same time as we expanded our pipeline of clinical programs with the initiation of two additional programs and the submission of one clinical trial application, more than doubling the portfolio." - Martin Welschof, CEO of BioInvent. Events...

Read more

Apollo Endosurgery, Inc. Reports 50% Revenue Growth in 2021

February 22, 2022 4:01 PM

Increased adoption across all product lines in both U.S. and international Grew fourth quarter 2021 revenue 26% AUSTIN, TX / ACCESSWIRE / February 22, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the fourth quarter and year ended December 31, 2021 and corporate highlights. Fourth Quarter and Full Year...

Read more

Viewpoint Molecular Targeting(R) to Present at the B. Riley Radiation Oncology Investor Day

February 22, 2022 9:30 AM

Fireside chat with newly appointed CEO, Thijs Spoor, today, February 22 at 1:30 PM ET CORALVILLE, IA / ACCESSWIRE / February 22, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced that Thijs Spoor, Chief Executive Officer of Viewpoint, will participate in a fireside chat at the B. Riley Radiation...

Read more

Viewpoint Molecular Targeting(R) Appoints Thijs Spoor as Chief Executive Officer

February 22, 2022 9:00 AM

Established leader with nearly 30 years of combined executive, broad management and capital markets expertise across healthcare and medical device industries CORALVILLE, IA / ACCESSWIRE / February 22, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, announced today the appointment of Thijs Spoor, MBA as its...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

February 22, 2022 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

Applied UV Enters Three Year Agreement Through its Scandinavian Distribution Partner Airocide Nordic Oy with Plandent Division for Distribution of Airocide(R) to Dental Providers

February 22, 2022 8:00 AM

Covers Finland with plans to expand throughout all of countries in Scandinavia and Europe MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and...

Read more